



June 16, 2006

Document Control Office

Docket AR-226

EPA East Building, Room 6428

1201 Constitution Ave., N.W.

Washington, DC 20460

Phone: 202-564-8930

Attention: OPPT Docket No. AR-226 (Mary Dominiak - Room 4410)

Re: Information on Perfluorooctane Sulfonate, Perfluorooctanoic Acid, and Related Compounds

Dear Ms. Dominiak:

This continues 3M's voluntary submissions of data on perfluorooctane sulfonate (PFOS), perfluorooctanoic acid (PFOA), and related compounds. We are enclosing for the docket paper copies of the following three studies:

- Final Report, "Pilot Study to Assess the Serum Fluorochemical Concentrations in American Red Cross Blood Donors, 2005," 3M Medical Department Epidemiology, 220-6W-08, January 9, 2006;
- Final Report, "Self-Reported Medical Conditions in Perfluorooctanesulfonyl Fluoride Manufacturing Workers," University of Minnesota School of Public Health, February 1, 2006; and
- Final Report, "An Analysis of the 2000 Fluorochemical (Perfluorooctanoate, PFOA) Medical Surveillance Program at 3M Company's Antwerp (Belgium), Cottage Grove (Minnesota), and Decatur (Alabama) Facilities," 3M Medical Department Epidemiology, 220-3W-05, May 16, 2006.

Please feel free to contact me with any questions.

Very truly yours,

Michael A. Santoro/KHR

Michael A. Santoro

Director of Environmental Health

Safety and Regulatory Affairs

Enterprise Services

3M Center, Building 236-1B-10

St. Paul, MN 55144

651-733-6374 (phone)

651-733-1958 (fax)

E-mail: masantoro@mmm.com

Enclosures

cc: Dr. Charles Auer
Dr. Jennifer Seed
Dr. Oscar Hernandez